These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 15723220

  • 1. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S.
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [Abstract] [Full Text] [Related]

  • 2. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, van Noort C, de Bruijn P, Verweij J.
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [Abstract] [Full Text] [Related]

  • 3. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P.
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion.
    Kaneta T, Fujita K, Akiyama Y, Kawara K, Sunakawa Y, Kawachi A, Shimada K, Sasaki Y.
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):539-47. PubMed ID: 25053387
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
    Xiong J, Zhao G, Yang S, Chen J.
    Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
    McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA.
    Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [Abstract] [Full Text] [Related]

  • 15. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [Abstract] [Full Text] [Related]

  • 16. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
    Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B, Adolescent Aprepitant in Cancer Study Group.
    Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.